Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Drugs

Retrieve available abstracts of 35 articles:
HTML format

Single Articles

    April 2024
  1. ZHU C, Pang S, Liu J, Duan Q, et al
    Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines.
    Drugs. 2024;84:403-423.
    PubMed     Abstract available

    February 2024
  2. SCHIMMEL J, Epperson LC, Aldy K, Wax P, et al
    Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry.
    Drugs. 2024;84:209-217.
    PubMed     Abstract available

    September 2023
    Remdesivir: A Review in COVID-19.
    Drugs. 2023;83:1215-1237.
    PubMed     Abstract available

    June 2023
  4. POLAK TB, Cucchi DGJ, Schelhaas J, Ahmed SS, et al
    Results from Expanded Access Programs: A Review of Academic Literature.
    Drugs. 2023;83:795-805.
    PubMed     Abstract available

    May 2023
  5. CHEN TY, Wang SI, Hung YM, Hartman JJ, et al
    Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study.
    Drugs. 2023;83:621-632.
    PubMed     Abstract available

    February 2023
  6. KEAM SJ
    Nirsevimab: First Approval.
    Drugs. 2023;83:181-187.
    PubMed     Abstract available

  7. XIE J, Brash JT, Turkmen C, Driessen S, et al
    Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
    Drugs. 2023;83:249-263.
    PubMed     Abstract available

    January 2023
  8. PLOCQUE A, Mitri C, Lefevre C, Tabary O, et al
    Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
    Drugs. 2023;83:1-36.
    PubMed     Abstract available

    August 2022
  9. HOY SM
    Amubarvimab/Romlusevimab: First Approval.
    Drugs. 2022;82:1327-1331.
    PubMed     Abstract available

    July 2022
    Desidustat: First Approval.
    Drugs. 2022;82:1207-1212.
    PubMed     Abstract available

    June 2022
  11. KEAM SJ
    Tixagevimab + Cilgavimab: First Approval.
    Drugs. 2022;82:1001-1010.
    PubMed     Abstract available

  12. KOUFAKIS T, Mustafa OG, Ajjan RA, Garcia-Moll X, et al
    From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
    Drugs. 2022;82:949-955.
    PubMed     Abstract available

    March 2022
  13. LAMB YN
    Nirmatrelvir Plus Ritonavir: First Approval.
    Drugs. 2022 Mar 19. pii: 10.1007/s40265-022-01692.
    PubMed     Abstract available

  14. HEO YA
    Sotrovimab: First Approval.
    Drugs. 2022;82:477-484.
    PubMed     Abstract available

  15. SYED YY
    Molnupiravir: First Approval.
    Drugs. 2022;82:455-460.
    PubMed     Abstract available

    February 2022
  16. MAZZA MG, Vai B, De Picker L, Benedetti F, et al
    Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:349-351.

  17. LENZE EJ, Reiersen AM, Facente SN
    Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:353-354.

    January 2022
  18. RIZK JG, Wenziger C, Tran D, Hashemi L, et al
    Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Drugs. 2022;82:43-54.
    PubMed     Abstract available

    December 2021
  19. FACENTE SN, Reiersen AM, Lenze EJ, Boulware DR, et al
    Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Drugs. 2021;81:2081-2089.
    PubMed     Abstract available

  20. SYED YY
    Regdanvimab: First Approval.
    Drugs. 2021;81:2133-2137.
    PubMed     Abstract available

    November 2021
  21. DEEKS ED
    Casirivimab/Imdevimab: First Approval.
    Drugs. 2021;81:2047-2055.
    PubMed     Abstract available

    September 2021
  22. AHMED N, Pezacki JP
    Reply to Zhang and Zhu "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1693-1695.

  23. ZHANG S, Zhu F
    Comment on: "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1691-1692.

    July 2021
  24. ROE MT, Patrick-Lake B, von Eschenbach AC
    Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.
    Drugs. 2021;81:1235-1237.

    June 2021
  25. VUORIO A, Kovanen PT
    Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
    Drugs. 2021;81:1125-1127.

    April 2021
  26. HEO YA
    Voclosporin: First Approval.
    Drugs. 2021;81:605-610.
    PubMed     Abstract available

  27. HUM C, Loiselle J, Ahmed N, Shaw TA, et al
    MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Drugs. 2021;81:517-531.
    PubMed     Abstract available

  28. TORRES-PENA JD, Perez-Belmonte LM, Fuentes-Jimenez F, Lopez Carmona MD, et al
    Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.
    Drugs. 2021;81:685-695.
    PubMed     Abstract available

    March 2021
  29. LAMB YN
    BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Drugs. 2021;81:495-501.
    PubMed     Abstract available

    December 2020
  30. LIN KJ, Schneeweiss S, Tesfaye H, D'Andrea E, et al
    Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.
    Drugs. 2020;80:1961-1972.
    PubMed     Abstract available

    October 2020
  31. CANTINI F, Goletti D, Petrone L, Najafi Fard S, et al
    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Drugs. 2020 Oct 17. pii: 10.1007/s40265-020-01421.
    PubMed     Abstract available

  32. HAJRA A, Mathai SV, Ball S, Bandyopadhyay D, et al
    Management of Thrombotic Complications in COVID-19: An Update.
    Drugs. 2020;80:1553-1562.
    PubMed     Abstract available

    September 2020
  33. VRACHATIS DA, Giotaki SG, Giannopoulos G, Deftereos S, et al
    Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19".
    Drugs. 2020;80:1499-1500.

  34. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".
    Drugs. 2020;80:1501-1503.

  35. BIANCONI V, Violi F, Fallarino F, Pignatelli P, et al
    Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
    Drugs. 2020;80:1383-1396.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.